CURRENT
ISSUE
1612

The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently diagnosed mild to moderate COVID-19 in patients who are ≥12 years old, weigh at least 40 kg, and are at high risk for progressing to severe disease and/or hospitalization (see Table 1).1

Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. Bamlanivimab is not authorized for use in patients who are hospitalized or require oxygen therapy because...  Continue reading

More from Issue 1612
Previous Issue: 1611      November 16, 2020
Coming Soon
Drugs for Asthma
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
Ofatumumab (Kesimpta) for Multiple Sclerosis
An EUA for Baricitinib for COVID-19
An EUA for Casirivimab and Imdevimab - A Monoclonal Antibody Combination for COVID-19
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
FROM
ISSUE
1612

The FDA has approved the antiviral drug remdesivir (Veklury – Gilead) for IV treatment of COVID-19 in hospitalized patients who are ≥12 years old and weigh ≥40 kg. Hospitalized children who are <12 years old or weigh <40 kg can receive remdesivir through an Emergency Use Authorization (EUA). Remdesivir is the first drug to be approved in the US for treatment of COVID-19.

MECHANISM OF ACTION ... Continue reading

 Tweets